|
1
|
Popovich JR, Kashyap S and Cassaro S:
Sarcoma. In: StatPearls. Treasure Island (FL). 2022.
|
|
2
|
Bui NQ, Wang DS and Hiniker SM:
Contemporary management of metastatic soft tissue sarcoma. Curr
Probl Cancer. 43:289–299. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Howitt BE, Sholl LM, Dal Cin P, Jia Y,
Yuan L, MacConaill L, Lindeman N, Kuo F, Garcia E, Nucci MR and
Quade BJ: Targeted genomic analysis of mullerian adenosarcoma. J
Pathol. 235:37–49. 2015. View Article : Google Scholar
|
|
4
|
Mirabello L, Zhu B, Koster R, Karlins E,
Dean M, Yeager M, Gianferante M, Spector LG, Morton LM, Karyadi D,
et al: Frequency of pathogenic germline variants in
cancer-susceptibility genes in patients with osteosarcoma. JAMA
Oncol. 6:724–734. 2020. View Article : Google Scholar
|
|
5
|
Koelsche C, Schrimpf D, Stichel D, Sill M,
Sahm F, Reuss DE, Blattner M, Worst B, Heilig CE, Beck K, et al:
Sarcoma classification by DNA methylation profiling. Nat Commun.
12:4982021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Steele CD and Pillay N: The genomics of
undifferentiated sarcoma of soft tissue: Progress, challenges and
opportunities. Semin Cancer Biol. 61:42–55. 2020. View Article : Google Scholar
|
|
7
|
Cancer Genome Atlas Research Network, .
Electronic address. simpleelizabeth.demicco@sinaihealthsystem.caCancer
Genome Atlas Research Network: Comprehensive and integrated genomic
characterization of adult soft tissue sarcomas. Cell.
171:950–965.e28. 2017. View Article : Google Scholar
|
|
8
|
Jensen S, Seidelin JB, LaCasse EC and
Nielsen OH: SMAC mimetics and RIPK inhibitors as therapeutics for
chronic inflammatory diseases. Sci Signal. 13:eaax82952020.
View Article : Google Scholar
|
|
9
|
Duan X, Liu X, Liu N, Huang Y, Jin Z,
Zhang S, Ming Z and Chen H: Inhibition of keratinocyte necroptosis
mediated by RIPK1/RIPK3/MLKL provides a protective effect against
psoriatic inflammation. Cell Death Dis. 11:1342020. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Otsubo K, Maeyashiki C, Nibe Y, Tamura A,
Aonuma E, Matsuda H, Kobayashi M, Onizawa M, Nemoto Y, Nagaishi T,
et al: Receptor-Interacting Protein Kinase 3 (RIPK3) inhibits
autophagic flux during necroptosis in intestinal epithelial cells.
FEBS Lett. 594:1586–1595. 2020. View Article : Google Scholar
|
|
11
|
Wu S, Xu C, Xia K, Lin Y, Tian S, Ma H, Ji
Y, Zhu F, He S and Zhang X: Ring closure strategy leads to potent
RIPK3 inhibitors. Eur J Med Chem. 217:1133272021. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Karlsson J, Holmquist Mengelbier L,
Ciornei CD, Naranjo A, O'Sullivan MJ and Gisselsson D: Clear cell
sarcoma of the kidney demonstrates an embryonic signature
indicative of a primitive nephrogenic origin. Genes Chromosomes
Cancer. 53:381–391. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ravi R, Noonan KA, Pham V, Bedi R,
Zhavoronkov A, Ozerov IV, Makarev E, Artemov A, Wysocki PT, Mehra
R, et al: Bifunctional immune checkpoint-targeted antibody-ligand
traps that simultaneously disable TGFβ enhance the efficacy of
cancer immunotherapy. Nat Commun. 9:7412018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zeng D, Li M, Zhou R, Zhang J, Sun H, Shi
M, Bin J, Liao Y, Rao J and Liao W: Tumor microenvironment
characterization in gastric cancer identifies prognostic and
immunotherapeutically relevant gene signatures. Cancer Immunol Res.
7:737–750. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang J, Sun J, Liu LN, Flies DB, Nie X,
Toki M, Zhang J, Song C, Zarr M, Zhou X, et al: Siglec-15 as an
immune suppressor and potential target for normalization cancer
immunotherapy. Nat Med. 25:656–666. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Tirosh I, Izar B, Prakadan SM, Wadsworth
MH II, Treacy D, Trombetta JJ, Rotem A, Rodman C, Lian C, Murphy G,
et al: Dissecting the multicellular ecosystem of metastatic
melanoma by single-cell RNA-seq. Science. 352:189–196. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Lin B, Wang S, Yao Y, Shen Y and Yang H:
Comprehensive co-expression analysis reveals TMC8 as a prognostic
immune-associated gene in head and neck squamous cancer. Oncol
Lett. 22:4982021. View Article : Google Scholar
|
|
18
|
Ding H, Gui XH, Lin XB, Chen RH, Cai HR,
Fen Y and Sheng YL: Prognostic value of MAC30 expression in human
pure squamous cell carcinomas of the lung. Asian Pac J Cancer Prev.
17:2705–2710. 2016.PubMed/NCBI
|
|
19
|
Mandal P, Berger SB, Pillay S, Moriwaki K,
Huang C, Guo H, Lich JD, Finger J, Kasparcova V, Votta B, et al:
RIP3 induces apoptosis independent of pronecrotic kinase activity.
Mol Cell. 56:481–495. 2014. View Article : Google Scholar
|
|
20
|
André S, Picard M, Cezar R, Roux-Dalvai F,
Alleaume-Butaux A, Soundaramourty C, Cruz AS, Mendes-Frias A, Gotti
C, Leclercq M, et al: T cell apoptosis characterizes severe
Covid-19 disease. Cell Death Differ. 29:1486–1499. 2022. View Article : Google Scholar
|
|
21
|
Chen X, Zhu R, Zhong J, Ying Y, Wang W,
Cao Y, Cai H, Li X, Shuai J and Han J: Mosaic composition of
RIP1-RIP3 signalling hub and its role in regulating cell death. Nat
Cell Biol. 24:471–482. 2022. View Article : Google Scholar
|
|
22
|
Jiang P, Gu S, Pan D, Fu J, Sahu A, Hu X,
Li Z, Traugh N, Bu X, Li B, et al: Signatures of T cell dysfunction
and exclusion predict cancer immunotherapy response. Nat Med.
24:1550–1558. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Racle J, de Jonge K, Baumgaertner P,
Speiser DE and Gfeller D: Simultaneous enumeration of cancer and
immune cell types from bulk tumor gene expression data. Elife.
6:e264762017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bieging KT, Mello SS and Attardi LD:
Unravelling mechanisms of p53-mediated tumour suppression. Nat Rev
Cancer. 14:359–370. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Liu Y, Sánchez-Tilló E, Lu X, Clem B,
Telang S, Jenson AB, Cuatrecasas M, Chesney J, Postigo A and Dean
DC: Rb1 family mutation is sufficient for sarcoma initiation. Nat
Commun. 4:26502013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Tian W, Li Y, Zhang J, Li J and Gao J:
Combined analysis of DNA methylation and gene expression profiles
of osteosarcoma identified several prognosis signatures. Gene.
650:7–14. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Coupienne I, Fettweis G and Piette J: RIP3
expression induces a death profile change in U2OS osteosarcoma
cells after 5-ALA-PDT. Lasers Surg Med. 43:557–564. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Tuohy JL, Somarelli JA, Borst LB, Eward
WC, Lascelles BD and Fogle JE: Immune dysregulation and
osteosarcoma: Staphylococcus aureus downregulates TGF-β and
heightens the inflammatory signature in human and canine
macrophages suppressed by osteosarcoma. Vet Comp Oncol. 18:64–75.
2020. View Article : Google Scholar
|
|
29
|
Castro FA, Ivansson EL, Schmitt M,
Juko-Pecirep I, Kjellberg L, Hildesheim A, Gyllensten UB and
Pawlita M: Contribution of TMC6 and TMC8 (EVER1 and EVER2) variants
to cervical cancer susceptibility. Int J Cancer. 130:349–355. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ramalho-Carvalho J, Gonçalves CS, Graça I,
Bidarra D, Pereira-Silva E, Salta S, Godinho MI, Gomez A, Esteller
M, Costa BM, et al: A multiplatform approach identifies miR-152-3p
as a common epigenetically regulated onco-suppressor in prostate
cancer targeting TMEM97. Clin Epigenetics. 10:402018. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ding H, Gui X, Lin X, Chen R, Ma T, Sheng
Y, Cai H and Fen Y: The prognostic effect of MAC30 expression on
patients with non-small cell lung cancer receiving adjuvant
chemotherapy. Technol Cancer Res Treat. 16:645–653. 2017.
View Article : Google Scholar
|
|
32
|
Xiao M, Li H, Yang S, Huang Y, Jia S, Wang
H, Wang J and Li Z: Expression of MAC30 protein is related to
survival and clinicopathological variables in breast cancer. J Surg
Oncol. 107:456–462. 2013. View Article : Google Scholar
|
|
33
|
Workenhe ST, Nguyen A, Bakhshinyan D, Wei
J, Hare DN, MacNeill KL, Wan Y, Oberst A, Bramson JL, Nasir JA, et
al: De novo necroptosis creates an inflammatory environment
mediating tumor susceptibility to immune checkpoint inhibitors.
Commun Biol. 3:6452020. View Article : Google Scholar
|
|
34
|
Bagchi S, Yuan R and Engleman EG: Immune
checkpoint inhibitors for the treatment of cancer: Clinical impact
and mechanisms of response and resistance. Annu Rev Pathol.
16:223–249. 2021. View Article : Google Scholar
|
|
35
|
Gyrd-Hansen M and Meier P: IAPs: From
caspase inhibitors to modulators of NF-kappaB, inflammation and
cancer. Nat Rev Cancer. 10:561–574. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Shekhar TM, Miles MA, Gupte A, Taylor S,
Tascone B, Walkley CR and Hawkins CJ: IAP antagonists sensitize
murine osteosarcoma cells to killing by TNFα. Oncotarget.
7:33866–33886. 2016. View Article : Google Scholar
|
|
37
|
Wu L, Chung JY, Cao T, Jin G, Edmiston WJ
III, Hickman S, Levy ES, Whalen JA, Abrams ES, Degterev A, et al:
Genetic inhibition of RIPK3 ameliorates functional outcome in
controlled cortical impact independent of necroptosis. Cell Death
Dis. 12:10642021. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kandel S, Adhikary P, Li G and Cheng K:
The TIM3/Gal9 signaling pathway: An emerging target for cancer
immunotherapy. Cancer Lett. 510:67–78. 2021. View Article : Google Scholar
|
